Latest Breaking News On - Focus area approach - Page 6 : comparemela.com

Astellas Completes Acquisition of Propella Therapeutics

Astellas Completes Acquisition of Propella Therapeutics
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Naoki okamuraWilliam moorePrnewswire astellas pharma incAstellas pharma incPropella therapeutics incPropella therapeuticsFocus area approach

Astellas Completes Acquisition Of Propella Therapeutics

Astellas Completes Acquisition Of Propella Therapeutics
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Naoki okamuraWilliam mooreAstellas pharma incPrnewswire astellas pharma incPropella therapeutics incPropella therapeuticsTime decemberFocus area approach

EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") contributed to the development of a pediatric formulation to treat schistosomiasis as a member of the Pediatric Praziquantel Consortium (Consortium). The Consortium announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive scientific opinion for arpraziquantel to treat one of the neglected tropical diseases, schistosomiasis, in preschool-aged chi

United kingdomNaoki okamuraTechnischen universitPublic health institute switzerlandMinistry of health kenyaNtds control division ugandaKenya medical research instituteDivision of vector borneAccess to healthMinistry of healthUnlimit health united kingdomDevelopment kenyaConsortium partnersMinistry of health ugandaPediatric praziquantel consortiumMakerere university school of public health uganda

PADCEV® (Enfortumab Vedotin-Ejfv) With KEYTRUDA® (Pembrolizumab) Approved By FDA As The First And Only ADC Plus PD-1 To Treat Advanced Bladder Cancer

PADCEV® (Enfortumab Vedotin-Ejfv) With KEYTRUDA® (Pembrolizumab) Approved By FDA As The First And Only ADC Plus PD-1 To Treat Advanced Bladder Cancer
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomUnited statesThomas powlesNaoki okamuraAhsan arozullahAndrea maddox smithPfizer incBarts cancer centerMerck sharp dohme corpAstellas pharma incHead of oncology developmentExchange commissionMerck co incEuropean society for medical oncologyDrug administration

PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer

PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomUnited statesAhsan arozullahThomas powlesNaoki okamuraAndrea maddox smithRoger danseyAstellas pharma incMerck co incEuropean society for medical oncologyBladder cancer advocacy networkExchange commissionCorporate communicationsMerck sharp dohme corpBarts cancer center